The global parkinson’s disease therapeutics market may expand robustly over the forecast period (2013 to 2019) owing to the introduction of newer therapies for treating this debilitating movement disorder. Non-invasive neurostimulation device, adipose derived stem cell therapy, and repetitive magnetic stimulation device are examples of the latest therapies. The irregular functioning of dopamine producing nerve cells leads to Parkinson’s disease.
Dopamine regulates & facilitates bodily movements by sending appropriate signals to the brain. This hormone also facilitates the smooth functioning of muscles. Main symptoms of Parkinson’s disease are slow movements, tremors in the limbs, and problems in walking and balancing. In extreme cases, a patient may have problems in swallowing, suffer from constipation & dementia, and even face speech disabilities.
For Market Research Report on “Parkinson's Disease Therapeutics Market” Visit - https://www.hexaresearch.com/research-report/parkinson-disease-therapeutics-industry
The worldwide Parkinson’s disease therapeutics Market is segmented on the basis of products and regions. According to products, the categories are drug therapy, ablative neurosurgery, deep brain stimulation device, and others. At present, the industry is led by the drug therapy segment in terms of revenues. Patent expirations of prime drugs, such as Agilect/Azilect and Stalevo/Comtan/Comtess may negatively impact the growth of this segment in the near future. However, a strong product pipeline may offset revenue losses because of patent expirations. Key products currently in the pipeline are GlaxoSmithKline’s IPX-066 and EMD Serono/Merck Serono/Newron Pharmaceutical’s MAO-B inhibitor safinamide. The list also includes Kyowa Hakko Kirin’s adenosine A2A receptor antagonist istradefylline. End users in the global industry are clinics, homecare settings, and hospitals.
Geographically, the global Parkinson’s Disease Therapeutics Market is categorized into Europe, Asia Pacific, North America, and Rest of the World. North America is a regional leader owing to high cases of this disease and a strong reimbursement policy. According to the PDF (Parkinson’s Disease Foundation), there are nearly 60000 Americans who are diagnosed with this ailment every year. Europe is anticipated to be the second largest market after North America over the forecast period. The region is driven by high R&D investments by most companies operating in this market. Brazil, China, and India are expected to be lucrative regions owing to presence of high unmet medical needs and introduction of alternative therapeutic options, such as deep brain stimulation devices. Prominent companies in the global Market are Orion Corporation, St. Jude Medical, Kyowa Hakko Kirin Co. Ltd., GlaxoSmithKline, and Teva Pharmaceuticals.
Recently, a French technology startup entered into a partnership with Fayet, a cane products manufacturer. Fayet has been handcrafting walking sticks since 1999. The two companies together created the “Smart Cane”. It is equipped with a number of movement sensors, including a gyroscope and an accelerometer. This walking stick directly connects with GSM networks and sends alerts via SMS, email, or call to caretakers and family members in case the concerned patient falls. This device doesn’t need to be connected with any other device.
Parkinson’s patients often experience “freezing” and are thus susceptible to falls and injuries. Active Protective is a device that is basically a belt that incorporates the “fall in progress” technology. It deploys airbag protection around the hip area just before the patient faces the impact. This takes place within a fraction of a second.